Re: [NMusers] Sad news about Dr. Ludden

[Vijay Ivaturi]

Dear All,

I am deeply saddened to hear this news. During my PhD in Minnesota, I had
the privilege of engaging with Dr. Ludden through Skype interactions. In
the advanced PK course taught by Dr. Bill Elmquist, we had a unique
assignment to write an essay on the scientific impact and life journey of a
notable scientist in the field of Pharmacometrics. I don't recall how I
chose Dr. Ludden, but he was incredibly welcoming and generously shared
numerous stories about his personal and professional experiences. I cherish
those conversations and the insights he provided. I hope to find this essay
in one of my emails, and if I do, I will share it with you

Rest in peace, Dr. Ludden.

Warm regards,

Vijay

On Mon, Aug 5, 2024 at 4:49 PM Rene Bruno  wrote:

> Dear all,
>
> This is indeed very sad. I concur with everyone. Ton was a very nice
> person, always open to listen to you and provide advice and support. II met
> with him a couple of times in the early 90ies and particularly in one
> formal meeting (probably in 1992) when he was heading Pharmacometry at FDA.
> He has been so supportive to my popPK/PD plans to support the filing of
> docetaxel (Taxotere) that when I got back in my company (Rhone Poulenc, now
> Sanofi) that the SVP of Regulatory asked me "what it is that you are doing?
> population PK Given such positive feedback from Tom (and FDA) I got
> full support to get the data and analysis done on time for the filing.
> Tom's support changed my life as well as the one of patients
> receiving Taxotere with the Boxed Warning about elevated hepatic enzymes
> (still in the US PI) and the dose adjustment in the EU SCP.
>
> I will be indebted to him forever.
>
> René
>
>
> 
>  Sans
> virus.www.avast.com
> 
> <#m_-7736047338385682954_DAB4FAD8-2DD7-40BB-A1B8-4E2AA1F9FDF2>
>
> Le ven. 2 août 2024 à 20:56, Riley, Steve  a
> écrit :
>
>> Dear NM-Users,
>>
>>
>>
>> Regrettably, I am writing to let you know that Dr. Ludden passed away
>> Tuesday evening, 30JUL2024.
>>
>> I was able to get there over the weekend prior to visit him and his
>> family.
>>
>> During his wakeful moments we had some good scientific discussions.
>>
>> We talked a lot about NONMEM and how its functionality and utility has
>> expanded since he retired. He was pleased to hear about the changes.
>>
>> He was surrounded by family for the days leading up to the end. They were
>> all appreciative that I was able to get there and tell him (and them) how
>> much he meant to all of us and the impact he had on our careers.
>>
>>
>>
>> I think memories of Dr. Ludden were characterized perfectly by Marc
>> Gastonguay, “I am forever grateful for the positive impact that Tom had on
>> my life and career, not to mention the tremendous, although often
>> underappreciated, contributions he made to the disciplines of clinical
>> pharmacology and pharmacometrics. His humble brilliance will be missed and
>> fondly remembered.”
>>
>>
>> Steve Riley
>>
>>
>>
>

-- 
~Vijay

Re: [NMusers] Sad news about Dr. Ludden

[Rene Bruno]

Dear all,

This is indeed very sad. I concur with everyone. Ton was a very nice
person, always open to listen to you and provide advice and support. II met
with him a couple of times in the early 90ies and particularly in one
formal meeting (probably in 1992) when he was heading Pharmacometry at FDA.
He has been so supportive to my popPK/PD plans to support the filing of
docetaxel (Taxotere) that when I got back in my company (Rhone Poulenc, now
Sanofi) that the SVP of Regulatory asked me "what it is that you are doing?
population PK Given such positive feedback from Tom (and FDA) I got
full support to get the data and analysis done on time for the filing.
Tom's support changed my life as well as the one of patients
receiving Taxotere with the Boxed Warning about elevated hepatic enzymes
(still in the US PI) and the dose adjustment in the EU SCP.

I will be indebted to him forever.

René


Sans
virus.www.avast.com

<#DAB4FAD8-2DD7-40BB-A1B8-4E2AA1F9FDF2>

Le ven. 2 août 2024 à 20:56, Riley, Steve  a écrit :

> Dear NM-Users,
>
>
>
> Regrettably, I am writing to let you know that Dr. Ludden passed away
> Tuesday evening, 30JUL2024.
>
> I was able to get there over the weekend prior to visit him and his
> family.
>
> During his wakeful moments we had some good scientific discussions.
>
> We talked a lot about NONMEM and how its functionality and utility has
> expanded since he retired. He was pleased to hear about the changes.
>
> He was surrounded by family for the days leading up to the end. They were
> all appreciative that I was able to get there and tell him (and them) how
> much he meant to all of us and the impact he had on our careers.
>
>
>
> I think memories of Dr. Ludden were characterized perfectly by Marc
> Gastonguay, “I am forever grateful for the positive impact that Tom had on
> my life and career, not to mention the tremendous, although often
> underappreciated, contributions he made to the disciplines of clinical
> pharmacology and pharmacometrics. His humble brilliance will be missed and
> fondly remembered.”
>
>
> Steve Riley
>
>
>

Re: [NMusers] Sad news about Dr. Ludden

[Alison Boeckmann]

Dear nmusers,
It is so sad that Tom Ludden is gone.  I remember well his many contributions 
to NONMEM.
He was one of Stuart's original fellows and thus one of  the original users of 
NONMEM. 
He was  the voice of calm during the panicky days after Stuart Beal's 
unexpected death.
Tom pitched in to help me finalize NONMEM 6 - a task I could never have done on 
my own.  
He was always calm and thoughtful and friendly and smart.
And then he was able to recruit  Bob Bauer (Tom recognized the need for an exit 
strategy!)
The many tributes to him in this nmusers thread are inspiring.
-- Alison Boeckmann 

On Fri, Aug 2, 2024, at 3:51 PM, Bauer, Robert wrote:
> Dear Nmusers:
> The PK/PD scientists here at ICON express our sincere condolences on the 
> passing of Tom Ludden.  As mentioned by several already, Tom was very 
> instrumental in transitioning the NONMEM software development from the labs 
> of Beal, Sheiner, and Boeckmann at UCSF, to Globomax, then to ICON.   The 
> development team at ICON was greatly aided in adding additional features from 
> NONMEM VI to NONMEM 7 with his expert direction and his connections with many 
> in the PK/PD modeling and population analysis community offering their inputs 
> regarding desired features (and fixing a few bugs!).   Tom continued with 
> ICON all the way through the development of NONMEM 7.2 before his retirement 
> in Spring 2011, and oversaw the incorporation of dynamic memory allocation, 
> as well as parallel computing that were first incorporated in that version, 
> which was a significant milestone in the performance of NONMEM.  In a 
> retirement speech some years ago Tom expressed that his greatest desire was 
> that he was useful to the PK/PD and pharmacometrics field.  He certainly 
> accomplished this in a way few of us can ever hope to achieve.
>  
>  
> Robert J. Bauer, Ph.D.
> Senior Director
> Pharmacometrics R&D
> ICON Early Phase
> 731 Arbor way, suite 100
> Blue Bell, PA 19422 
> Office: (215) 616-6428
> Mobile: (925) 286-0769
> robert.ba...@iconplc.com
> www.iconplc.com
>  
> 
> 
> ICON plc made the following annotations. 
> --
>  
> This e-mail transmission may contain confidential or legally privileged 
> information that is intended only for the individual or entity named in the 
> e-mail address. If you are not the intended recipient, you are hereby 
> notified that any disclosure, copying, distribution, or reliance upon the 
> contents of this e-mail is strictly prohibited. If you have received this 
> e-mail transmission in error, please reply to the sender, so that ICON plc 
> can arrange for proper delivery, and then please delete the message. 
> 
> Thank You, 
> 
> ICON plc 
> South County Business Park 
> Leopardstown 
> Dublin 18 
> Ireland 
> Registered number: 145835

-- 
  Alison Boeckmann
  alisonboeckm...@fastmail.fm

RE: [NMusers] Sad news about Dr. Ludden

[Mark Sale]

We're very fortunate in this field to have an abundance or leaders who seem 
entirely motivated by advancing the field and helping others with their 
professional development.  In my limited experience, more so than any other 
field of bio medial research. Few however were as patient and generous as Tom. 
Many in this group are probably aware of the story of how he came to have 
NONMEM license #1 and how he was one of the few who gained Stuart's trust and 
respect early in the history of PMX, and the critical role he played in bring 
these methods into mainstream pharmaceutical research, a testament to both his 
technical knowledge and leadership skills. Like many others I personally 
benefited from my interactions with him.

Mark


Mark Sale M.D.
Vice President
Integrated Drug Development
mark.s...@certara.com
Remote-Forestville CA
Office Hours 9 AM - 5 PM Eastern Time
+1 302-516-1684
www.certara.com
[Certara Logo]

From: owner-nmus...@globomaxnm.com  On Behalf Of 
Nick Holford
Sent: Saturday, August 3, 2024 1:20 AM
To: nmusers@globomaxnm.com
Subject: RE: [NMusers] Sad news about Dr. Ludden

CAUTION: This email originated from outside of Certara. Do not click links or 
open attachments unless you recognize the sender and know the content is safe.


Thanks to nmusers for informing me of this sad news. I have known Tom for many 
years but we only occasionally met face to face. I echo the sentiments of 
others below who spoke of his depth of knowledge and gentleness. He helped me 
many times when I was struggling with NONMEM and I think we always found a 
solution. We wrote one publication together, a book chapter on the "Time Course 
of Drug Effect". This echoed what is my earliest citation of Tom's scientific 
contributions nearly 40 years age (Svec JM, Coleman RW, Mungall DR, Ludden TM. 
Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to 
warfarin therapy: preliminary evaluation. Ther Drug Monit. 1985;7(2):174-80.).

Tom, I hope in your afterlife you will still be able to follow nmusers. Thank 
you for all you have given to so many of us.

--
Nick Holford, Professor Emeritus Clinical Pharmacology, MBChB, FRACP
mobile: NZ+64(21) 46 23 53 ; FR+33(6) 62 32 46 72
email: n.holf...@auckland.ac.nz<mailto:n.holf...@auckland.ac.nz>
web: http://holford.fmhs.auckland.ac.nz/

From: owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com> 
mailto:owner-nmus...@globomaxnm.com>> On Behalf 
Of Patel, Bela
Sent: Saturday, August 3, 2024 1:43 AM
To: ENE ETTE mailto:ene_e...@anoixiscorp.com>>; Diane 
Mould mailto:drmo...@pri-home.net>>; Riley, Steve 
mailto:steve.ri...@pfizer.com>>; 
nmusers@globomaxnm.com<mailto:nmusers@globomaxnm.com>
Subject: RE: [External email][NMusers] Sad news about Dr. Ludden

Some people who received this message don't often get email from 
bela.pa...@merck.com<mailto:bela.pa...@merck.com>. Learn why this is 
important<https://aka.ms/LearnAboutSenderIdentification>

Public

Dear All,
I am extremely saddened to hear this news. As mentioned by Ene, Dr. Tom Ludden 
was one of the pioneers in advancing pharmacometrics along with Dr. Beal and 
Dr. Sheiner promoting its value and impact in drug discovery and development as 
well as acceptance by the FDA. He provided invaluable scientific advice and 
trained numerous scientists in pharmacometrics. He was a real gentle soul and 
it was truly a privilege to have known him and be tutored by him.

May his soul rest in peace.

Sincerely,
Bela

From: owner-nmus...@globomaxnm.com<mailto:owner-nmus...@globomaxnm.com> 
mailto:owner-nmus...@globomaxnm.com>> On Behalf 
Of ENE ETTE
Sent: Friday, August 2, 2024 5:30 PM
To: Diane Mould mailto:drmo...@pri-home.net>>; Riley, 
Steve mailto:steve.ri...@pfizer.com>>; 
nmusers@globomaxnm.com<mailto:nmusers@globomaxnm.com>
Subject: RE: [External email][NMusers] Sad news about Dr. Ludden

Some people who received this message don't often get email from 
ene_e...@anoixiscorp.com<mailto:ene_e...@anoixiscorp.com>. Learn why this is 
important<https://aka.ms/LearnAboutSenderIdentification>
EXTERNAL EMAIL- Use caution with any links or file attachments.
Dear All:
In Dr. Ludden we lost an excellent scientist who helped to revolutionize and 
advance clinical pharmacokinetics, pharmacometrics, clinical pharmacology, and 
drug development. I'm indebted to him for the impact he made on my life as a 
pharmacometrician, clinical pharmacologist, and drug developer while working 
with him at the FDA. He started the Pharmacometrics Staff Unit which became 
Pharmacometrics Division in later years.

May his soul rest in peace.

Sincerely,
Ene.

Sent from Mail<https://go.microsoft.com/fwlink/?LinkId=550986> for Windows

From: Diane Mould<mailto:drmo...@pri-home.net>
Sent: Friday, August 2, 2024 4:03 PM
To: Riley, Steve<mailto:steve.ri...@pfizer.com>; 
n

RE: [NMusers] Sad news about Dr. Ludden

[Nick Holford]

Thanks to nmusers for informing me of this sad news. I have known Tom for many 
years but we only occasionally met face to face. I echo the sentiments of 
others below who spoke of his depth of knowledge and gentleness. He helped me 
many times when I was struggling with NONMEM and I think we always found a 
solution. We wrote one publication together, a book chapter on the “Time Course 
of Drug Effect”. This echoed what is my earliest citation of Tom’s scientific 
contributions nearly 40 years age (Svec JM, Coleman RW, Mungall DR, Ludden TM. 
Bayesian pharmacokinetic/pharmacodynamic forecasting of prothrombin response to 
warfarin therapy: preliminary evaluation. Ther Drug Monit. 1985;7(2):174-80.).

Tom, I hope in your afterlife you will still be able to follow nmusers. Thank 
you for all you have given to so many of us.

--
Nick Holford, Professor Emeritus Clinical Pharmacology, MBChB, FRACP
mobile: NZ+64(21) 46 23 53 ; FR+33(6) 62 32 46 72
email: n.holf...@auckland.ac.nz
web: http://holford.fmhs.auckland.ac.nz/

From: owner-nmus...@globomaxnm.com  On Behalf Of 
Patel, Bela
Sent: Saturday, August 3, 2024 1:43 AM
To: ENE ETTE ; Diane Mould ; 
Riley, Steve ; nmusers@globomaxnm.com
Subject: RE: [External email][NMusers] Sad news about Dr. Ludden

Some people who received this message don't often get email from 
bela.pa...@merck.com. Learn why this is 
important

Public

Dear All,
I am extremely saddened to hear this news. As mentioned by Ene, Dr. Tom Ludden 
was one of the pioneers in advancing pharmacometrics along with Dr. Beal and 
Dr. Sheiner promoting its value and impact in drug discovery and development as 
well as acceptance by the FDA. He provided invaluable scientific advice and 
trained numerous scientists in pharmacometrics. He was a real gentle soul and 
it was truly a privilege to have known him and be tutored by him.

May his soul rest in peace.

Sincerely,
Bela

From: owner-nmus...@globomaxnm.com 
mailto:owner-nmus...@globomaxnm.com>> On Behalf 
Of ENE ETTE
Sent: Friday, August 2, 2024 5:30 PM
To: Diane Mould mailto:drmo...@pri-home.net>>; Riley, 
Steve mailto:steve.ri...@pfizer.com>>; 
nmusers@globomaxnm.com
Subject: RE: [External email][NMusers] Sad news about Dr. Ludden

Some people who received this message don't often get email from 
ene_e...@anoixiscorp.com. Learn why this is 
important
EXTERNAL EMAIL– Use caution with any links or file attachments.
Dear All:
In Dr. Ludden we lost an excellent scientist who helped to revolutionize and 
advance clinical pharmacokinetics, pharmacometrics, clinical pharmacology, and 
drug development. I’m indebted to him for the impact he made on my life as a 
pharmacometrician, clinical pharmacologist, and drug developer while working 
with him at the FDA. He started the Pharmacometrics Staff Unit which became 
Pharmacometrics Division in later years.

May his soul rest in peace.

Sincerely,
Ene.

Sent from Mail for Windows

From: Diane Mould
Sent: Friday, August 2, 2024 4:03 PM
To: Riley, Steve; 
nmusers@globomaxnm.com
Subject: RE: [External email][NMusers] Sad news about Dr. Ludden

Dear All
I am very saddened to hear this news.  Tom Ludden was one of the nicest and 
smartest people that I have ever known.  He was a gentle giant in our field and 
I will miss him.
Best
Diane

From: owner-nmus...@globomaxnm.com 
mailto:owner-nmus...@globomaxnm.com>> On Behalf 
Of Riley, Steve
Sent: Friday, August 2, 2024 2:41 PM
To: nmusers@globomaxnm.com
Subject: [External email][NMusers] Sad news about Dr. Ludden


CAUTION: This email originated from outside the organization. Do not click 
links or open attachments unless you recognize the sender and know the content 
is safe.
Dear NM-Users,

Regrettably, I am writing to let you know that Dr. Ludden passed away Tuesday 
evening, 30JUL2024.

I was able to get there over the weekend prior to visit him and his family.
During his wakeful moments we had some good scientific discussions.
We talked a lot about NONMEM and how its functionality and utility has expanded 
since he retired. He was pleased to hear about the changes.

He was surrounded by family for the days leading up to the end. They were all 
appreciative that I was able to get there and tell him (and them) how much he 
meant to all of us and the impact he had on our careers.

I think memories of Dr. Ludden were characterized perfectly by Marc Gastonguay, 
“I am forever grateful for the positive impact that Tom had on my life and 
career, not to mention the tremendous, although often underappreciated, 
cont